Cargando…

Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation

BACKGROUND: The anticoagulation of atrial fibrillation catheter ablation during the perioperative stage does matter and should be treated with discretion. We aimed to assess impact of three important genes participating in vitamin K cycle (i.e. VKORC1 rs9923231, CYP4F2 rs2108622 and NQO1 rs1800566)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jiao, Yang, Wenlong, Xie, Zhonghui, Yu, Kun, Chen, Yuhua, Cui, Kaijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960187/ https://www.ncbi.nlm.nih.gov/pubmed/29776386 http://dx.doi.org/10.1186/s12872-018-0837-x

Ejemplares similares

Polymorphisms of CYP2C9*2, CYP2C9*3 and VKORC1 genes related to time in therapeutic range in patients with atrial fibrillation using warfarin
por: da Silveira, Maria Mariana Barros Melo, et al.
Publicado: (2019)

Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population
por: Jia, LiQun, et al.
Publicado: (2017)

Methylation of CYP1A1 and VKORC1 promoter associated with stable dosage of warfarin in Chinese patients
por: He, Shiwei, et al.
Publicado: (2021)

Effects of VKORC1 Genetic Polymorphisms on Warfarin Maintenance Dose Requirement in a Chinese Han Population
por: Yan, Xiaojuan, et al.
Publicado: (2015)

Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis
por: Zhang, Jinhua, et al.
Publicado: (2016)

Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction
por: Haug, Kari Bente Foss, et al.
Publicado: (2008)

VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients
por: Park, Sea Mi, et al.
Publicado: (2013)

Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy
por: Poopak, Behzad, et al.
Publicado: (2015)

Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine
por: Ayesh, Basim Mohammad, et al.
Publicado: (2018)

VKORC1 variants as significant predictors of warfarin dose in Emiratis
por: Al-Mahayri, Zeina N, et al.
Publicado: (2019)

Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: Test Category: Pharmacogenomic (Treatment)
por: Grossniklaus, Daurice
Publicado: (2010)

Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis
por: Jorgensen, Andrea L., et al.
Publicado: (2012)

Warfarin Dosing in a Patient with CYP2C9(∗)3(∗)3 and VKORC1-1639 AA Genotypes
por: Johnson, Mark, et al.
Publicado: (2014)

Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy
por: AL-Eitan, Laith N., et al.
Publicado: (2019)

The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population
por: Taşkın, Birce Dilge, et al.
Publicado: (2016)

Determination of Pleiotropic Effect of Warfarin in VKORC1 and CYP2C9 Genotypes in Patients With Heart Valve Replacement
por: Shafique, Huma, et al.
Publicado: (2022)

The effect of the VKORC1 promoter variant on warfarin responsiveness in the Saudi WArfarin Pharmacogenetic (SWAP) cohort
por: Al Ammari, Maha, et al.
Publicado: (2020)

The Contribution of VKORC1 and CYP2C9 Genetic Polymorphisms and Patients’ Demographic Characteristics with Warfarin Maintenance Doses: A Suggested Warfarin Dosing Algorithm
por: Khaleqsefat, Esmat, et al.
Publicado: (2020)

Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population
por: Hadjipanagi, Despina, et al.
Publicado: (2014)

Genetic Variation of VKORC1 and CYP4F2 Genes Related to Warfarin Maintenance Dose in Patients with Myocardial Infarction
por: Kringen, Marianne K., et al.
Publicado: (2011)

VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People
por: Henderson, Lindsay M., et al.
Publicado: (2019)

Catheter Ablation for Atrial Fibrillation
por: Gauri, Andre J, et al.
Publicado: (2003)

Early Experience of Novel Oral Anticoagulants in Catheter Ablation for Atrial Fibrillation: Efficacy and Safety Comparison to Warfarin
por: Shin, Dong Geum, et al.
Publicado: (2016)

Association of Warfarin Therapy with APOE and VKORC1 Genes Polymorphism in Iranian Population
por: Rafiee, Sajad, et al.
Publicado: (2017)

Impact of CYP2C9 and VKORC1 Polymorphisms on Warfarin Sensitivity and Responsiveness in Jordanian Cardiovascular Patients during the Initiation Therapy
por: AL-Eitan, Laith N., et al.
Publicado: (2018)

A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
por: Takeuchi, Fumihiko, et al.
Publicado: (2009)

Frequency of polymorphisms in the CYP2C9, VKORC1, and CYP4F2 genes related to the metabolism of Warfarin in healthy donors from Cali, Colombia
por: Giraldo-Ocampo, Sebastian, et al.
Publicado: (2023)

Safety and efficacy of uninterrupted treatment with edoxaban or warfarin during the peri‐procedural period of catheter ablation for atrial fibrillation
por: Naito, Kazuya, et al.
Publicado: (2020)

Cryoballoon Catheter Ablation in Atrial Fibrillation
por: Ozcan, Cevher, et al.
Publicado: (2011)

Catheter ablation of atrial fibrillation in the elderly
por: Lioni, Louiza, et al.
Publicado: (2014)

Height, VKORC1 1173, and CYP2C9 Genotypes Determine Warfarin Dose for Pediatric Patients with Kawasaki Disease in Southwest China
por: Yang, Dan, et al.
Publicado: (2018)

Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit
por: Biswas, Mansij, et al.
Publicado: (2018)

Hybrid atrial fibrillation ablation in patients with persistent atrial fibrillation or failed catheter ablation
por: Al-Jazairi, M. I. H., et al.
Publicado: (2019)

Hyper-responsiveness to warfarin in a young patient with the VKORC1 -1639GA/CYP2C9*1*46 genotype: a case report
por: Aldiban, Weam, et al.
Publicado: (2022)

Comparison of direct oral anticoagulants and warfarin regarding midterm adverse events in patients with atrial fibrillation undergoing catheter ablation
por: Sagawa, Yuichiro, et al.
Publicado: (2018)

Editorial to “Safety and Efficacy of Uninterrupted Treatment with Edoxaban or Warfarin During the Peri‐Procedural Period of Catheter Ablation for Atrial Fibrillation”
por: Fukaya, Hidehira
Publicado: (2020)

The effect of CYP2C9*2, CYP2C9*3, and VKORC1-1639 G>A polymorphism in patients under warfarin therapy in city of Kermanshah
por: Hosseinkhani, Zohreh, et al.
Publicado: (2018)

Catheter ablation of atrial fibrillation in elderly population
por: Kautzner, Josef, et al.
Publicado: (2017)

Atrial Fibrillation Mechanisms and Implications for Catheter Ablation
por: Cheniti, Ghassen, et al.
Publicado: (2018)

Catheter ablation in patients with persistent atrial fibrillation
por: Kirchhof, Paulus, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cchs49et4idhf0ifa1phr941hc